The British government has therefore signed two partnerships: one with BionTech to provide access to 10,000 patients by 2030 patients, and a ten-year investment with modern in an innovation and technological center with the ability to produce up to 250 million vaccines. The stars were in line.

During the pandemic, the UK opened clinical trials within a few weeks. But before it took years to complete a clinical trial. What has changed?

It was really fascinating, because for many years we believed that research is inherently slow. It took earlier 20 years to get a drug on the market. Unfortunately, most cancer patients will succumb to the market to the market. We have shown the world that it can be done in a year if your process modernizes, parts of the process parallel and use digital tools.

Of course, opening a clinical trial during a pandemic is not necessarily the same as a clinical trial for cancer. But at an early stage you had a breakthrough for the cancer vaccine project.

There was a trial by Biontech, called BNT122, on people at high risk intestinal cancer, who did not recruit very well around the world. When we announced the cancer launch block, the British cancer community took the opportunity. We opened that trial at Birmingham University Hospital, which was most surprising to me, because it is not a leading center for cancer vaccine studies.

We had to find 10,000 patients enrolled in the hearing, and we got there within three months. It was quite incredible. It just shows that because we are a single healthcare system, we can do it faster than any other country.

The dominoes began to fall on the back of the success very quickly: we opened a trial and neck cancer trial in Liverpool, a esophagus and stomach cancer trial in Dundee, and a lung cancer hearing in London. We have begun to create a community of people who can all start cancer vaccine trials as quickly as possible.

Several MRNA-based cancer vaccines are internationally in clinical trials in the late stage, and the UK is currently exporting 15 Cancer Incine trials. When do we see the first approved MRNA cancer vaccine?

We have a hearing to stop skin cancer from returning after you cut it out. It is now complete. We received too much again, just like each of the trials we did, and the trial ended one year before the schedule. This is completely unheard of in cancer trials because they are usually too long.

What is going to happen now is that over the next six to 12 months we will monitor and practice the people in the hearing if there is a difference between the people who have taken the cancer vaccine and those who did not. We hope to have results by the end of the year or beginning of 2026. If successful, we will invent the first approved Personalized MRNA vaccine in just five years after the first licensed MRNA vaccine for Covid. It’s pretty impressive.

Hear Lennard Lee speaks on March 18 at Wired Health on Kings Place, London. Get tickets at health.wired.com.